Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 37

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 37
---
 21, 2025, the Record Date, there were 43,108,362 Common Shares issued and outstanding.                                                                                                                                                       |

17

| Q: | What vote is required to approve the Compensation Resolution, Liquidation Resolution and Liquidator 
 Resolution?                                                                                         |

| A: | Approval of the Compensation Resolution requires the affirmative vote of a majority of the votes cast by                                                             
 Shareholders present in person or represented by proxy at the Special meeting. Approval of the Liquidation Resolution requires the affirmative vote of not less than 
 662⁄3% of the votes cast by Shareholders present in person (virtually) or represented by proxy at the Special Meeting. Approval of the Liquidator Resolution         
 requires the affirmative vote of not less than 662⁄3% of the votes cast by Shareholders present in person (virtually) or represented by proxy at the Special         
 Meeting.                                                                                                                                                             |

| Q: | What effects will the Arrangement have on the Company? |

| A: | Our Common Shares are currently registered under the U.S. Securities Exchange Act of 1934, as amended (the 
 “Exchange Act”) and are traded on Nasdaq Global Select Market (“Nasdaq”) under the trading symbol “RPTX.”  |

Following the consummation of the Arrangement, all the Common Shares will be owned by the Purchaser. In connection with the Arrangement, the Common Shares will be delisted from Nasdaq and deregistered under the Exchange Act, in each case, in accordance with applicable laws, rules and regulations, and the Company will no longer have reporting obligations with respect to the Common Shares under the Exchange Act. Similarly, it is anticipated that the Company will apply to cease to be a reporting issuer (or equivalent) in Québec and that it will cease to have public reporting obligations under securities laws following completion of the Arrangement.

| Q: | What court approvals are required for the Arrangement? |

| A: | Under the QBCA, the Arrangement requires approval by the Superior Court of Quebec (Commercial Division). On                                                                                                                                              
 December  , 2025, the Company obtained the Interim Order providing for the calling and holding of the Special Meeting, the Dissent Rights and other procedural matters. Subject to the approval of the Arrangement Resolution by the Shareholders        
 at the Special Meeting, the Company intends to make an application to the Court for the Final Order approving the Arrangement. Assuming that the Final Order is granted, the Company will file